Sera Prognostics, Inc. (SERA) vs Verrica Pharmaceuticals Inc. (VRCA)
A side-by-side comparison of Sera Prognostics, Inc. and Verrica Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SERA
Sera Prognostics, Inc.
$2.05HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VRCA
Verrica Pharmaceuticals Inc.
$4.21HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — SERA vs VRCA
growth of $100 · dividends reinvested · last 5ySERA -83.2% (-30.0%/yr)VRCA -95.9% (-47.2%/yr)SERA compounded faster over this window
SERA VRCA
SERA vs VRCA: by the numbers
- •SERA is the larger company ($78M vs $72M market cap).
- •Both run net losses; VRCA's is the smaller (-102.84% vs -47475.71% net margin).
- •VRCA grew revenue faster over the past five years (20.37% vs 9.73% CAGR).
Metrics side by side
Valuation
| Metric | SERA | VRCA |
|---|---|---|
| P/S ratio | 1118.45 | 2.39 |
| P/B ratio | 1.32 | 16.79 |
Profitability
| Metric | SERA | VRCA |
|---|---|---|
| Gross margin | -102.47% | 85.89% |
| Operating margin | -45066.67% | -33.56% |
| Net margin | -47475.71% | -102.84% |
| ROE | -55.97% | -724.01% |
| ROIC | -59.79% | -207.23% |
Growth (annualized)
| Metric | SERA | VRCA |
|---|---|---|
| Revenue CAGR (5Y) | 9.73% | 20.37% |
| Total return CAGR (5Y) | -28.91% | -48.68% |
Frequently asked
- Which has grown faster, SERA or VRCA?
- Over the past five years, VRCA grew revenue faster — SERA at a 9.73% CAGR versus VRCA at 20.37%.
- How have SERA and VRCA total returns compared?
- Over the past 5 years, SERA delivered -28.91% and VRCA delivered -48.68% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Sera Prognostics ROEVerrica Pharmaceuticals ROESera Prognostics operating marginVerrica Pharmaceuticals operating marginSera Prognostics revenue growthVerrica Pharmaceuticals revenue growthSera Prognostics free cash flowVerrica Pharmaceuticals free cash flow
Sera Prognostics & Verrica Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.